RET and lung adenocarcinoma: Using ponatinib as an MKI to counteract RET fusion-positive (CCDC6-RET) LC-2/ad lung adenocarcinoma cell growth, Nelson-Taylor and colleagues demonstrated that inhibition of RET phosphorylation is accompanied by ERK1/2 and AKT inactivation [74].